BELITE BIO INC ADR
NASDAQ: BLTE (Belite Bio, Inc)
Kemas kini terakhir: 8 jam lalu170.96
0.61 (0.36%)
| Penutupan Terdahulu | 170.35 |
| Jumlah Dagangan | 90,694 |
| Harga / Pendapatan (P/E Ke hadapan) | 434.78 |
| Harga / Buku (P/B) | 8.87 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.37% |
| Nisbah Semasa (MRQ) | 25.98 |
| Aliran Tunai Operasi (OCF TTM) | -29.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -13.42 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -33.43% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Belite Bio, Inc | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.25 |
|
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.93% |
| % Dimiliki oleh Institusi | 0.75% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Darwin Global Management, Ltd. | 30 Jun 2026 | 3,077,219 |
| Maverick Capital Ltd | 30 Jun 2026 | 396,311 |
| Eventide Asset Management, Llc | 30 Jun 2026 | 390,829 |
| Holocene Advisors, Lp | 30 Jun 2026 | 251,035 |
| Mpm Bioimpact Llc | 30 Jun 2026 | 137,208 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| CHUANG HAO-YUAN | - | 192.85 | -17,962 | -3,463,972 |
| LIN YU-HSIN | - | 192.85 | -26,000 | -5,014,100 |
| Jumlah Keseluruhan Kuantiti Bersih | -43,962 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -8,478,072 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 192.85 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| CHUANG HAO-YUAN | Pegawai | 08 Sep 2026 | Jual automatik (-) | 17,962 | 192.85 | 3,463,972 |
| LIN YU-HSIN | Pegawai | 08 Sep 2026 | Jual automatik (-) | 26,000 | 192.85 | 5,014,100 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |